Efficacy and Safety of Long-term Oral Administration of Staphylococcus Albicans Tablets in Patients With Acute Exacerbation and Stable Bronchiectasis: a Multicenter, Prospective Randomized Controlled Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 134
- 试验地点
- 1
- 主要终点
- Number of acute exacerbations
研究概览
简要总结
The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.
详细描述
Bronchiectasis is a chronic airway purulent disease. The four factors of "vicious circle" play an important role in the occurrence, development and prognosis of bronchiectasis. Attempts to breaks the vicious circle may be beneficial to reduce the acute exacerbation of bronchiectasis. The main ingredients of Staphylococcus albicans tablets are the inactivated cells of Staphylococcus albus, Catarella catarrhalis and Bacillus subtilis. It may be beneficial to improve the non-specific immunity of patients and the specific immune function of respiratory mucosa, and reduce airway mucus secretion and secretion retention. There is not yet sufficient clinical evidence to support the immune function regulation and related efficacy of patients. Therefore, the efficacy of long-term oral administration of Staphylococcus albicans tablets in patients with bronchiectasis needs to be further confirmed by clinical studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;
- •Patients with idiopathic or post-infectious bronchiectasis;
- •18years old;
- •Patients should have at least 2 acute exacerbations within 1 year before enrollment;
- •Patients in either acute exacerbation or stable period can be included.
排除标准
- •Cystic fibrosis;
- •Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;
- •Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;
- •Still smoking;
- •Complicated with asthma or chronic obstructive disease Lung;
- •Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;
- •Malignant tumors;
- •Allergy to Staphylococcus albicans tablets;
- •Patients with a history of gastric ulcer or intestinal malabsorption;
- •Pregnant or lactating women;
- •patients with poor compliance;
- •previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;
- •Patients who are participating in or have participated in interventional clinical trials within 3 months.
研究组 & 干预措施
Experimental group
Oral staphylococcus albicans tablet group.
干预措施: Staphylococcus and Neisseria Tablets (Drug)
Control group
On-demand treatment group
干预措施: On-demand treatment (Other)
结局指标
主要结局
Number of acute exacerbations
时间窗: Up to 3 months
Time to first exacerbation
时间窗: Up to 12 months
Rate of readmission at 12 months
时间窗: Up to 12 months
次要结局
- Change from Baseline Life Quality Score at 12 months(Up to 12 months)
- Change from Baseline FEV1 at 12 months(Up to 12 months)
- Change from Baseline FEV1/FVC at 12 months(Up to 12 months)
- Change from Baseline FEV1 % predicted at 12 months(Up to 12 months)
- Change from Baseline sputum volume at 12 months(Up to 12 months)
- Change from Baseline percentage of patients with yellow purulent sputum at 12 months(Up to 12 months)
- Change from Baseline percentage of patients with immune dysfunction at 12 months(Up to 12 months)
- Change from Baseline of percentage of patients with positive sputum culture(Up to 12 months)
- Number of Participants with adverse reactions(Up to 12 months)
研究者
Qian Qi
Principal Investigator
Qianfoshan Hospital